125 related articles for article (PubMed ID: 1008080)
41. [Comparison of the efficacy of imidazole-carboxamide and of a combination of nitrosomethylurea, vincristine and dactinomycin in disseminated melanoma].
Kogoniia LM; Moroz LV; Perevodchikova NI; Platinskiĭ LV; Borisov AI
Vopr Onkol; 1981; 27(4):16-21. PubMed ID: 7015692
[TBL] [Abstract][Full Text] [Related]
42. [Cancer immunotherapy in dermatological view (author's transl)].
Lübbe D; Gstöttner R
Arch Geschwulstforsch; 1980; 50(2):182-5. PubMed ID: 7436703
[TBL] [Abstract][Full Text] [Related]
43. Multimodality therapy in the treatment of regionally inoperable melanomas and sarcomas.
Yeager RA; Eidemiller LR; Fletcher WS
Surg Gynecol Obstet; 1975 Sep; 141(3):367-70. PubMed ID: 1162562
[TBL] [Abstract][Full Text] [Related]
44. Adjuvant immunotherapy for vulvar malignant melanoma.
Wallach RC; Taub RN
Mt Sinai J Med; 1979; 46(2):161-2. PubMed ID: 312443
[No Abstract] [Full Text] [Related]
45. Use of methyl-CCNU and procarbazine in advanced malignant melanoma resistant to DTIC therapy.
Didolkar MS; Baffi RR; Catane R; Kaufman J; Holyoke ED
Cancer Treat Rep; 1977 Dec; 61(9):1738-9. PubMed ID: 597824
[No Abstract] [Full Text] [Related]
46. [Multiple BCG-induced ulcers after subcutaneous vaccination in the framework of immunochemotherapy in malignant melanoma].
Korting HC; Strasser S; Konz B
Hautarzt; 1988 Mar; 39(3):170-3. PubMed ID: 3378889
[TBL] [Abstract][Full Text] [Related]
47. Adjuvant immunotherapy of malignant melanoma.
Aranha GV; McKhann CF; Grage TB; Gunnarsson A; Simmons RL
Cancer; 1979 Apr; 43(4):1297-303. PubMed ID: 445331
[TBL] [Abstract][Full Text] [Related]
48. [Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
Perrot JL; Lanthier K; Benoit F; Graille MC; Guy C; Bertheas MF; Cambazard F
Ann Dermatol Venereol; 1995; 122(10):663-6. PubMed ID: 8687048
[TBL] [Abstract][Full Text] [Related]
49. [Recent controlled studies on the therapy of malignant melanoma].
Canavese G; Margarino G
Minerva Med; 1982 Dec; 73(48):3458-60. PubMed ID: 6757800
[No Abstract] [Full Text] [Related]
50. Immunotherapeutic activity of percutaneous BCG vaccine: laboratory and clinical studies.
Engibarov A; Chouchkova M; Ikonopisov R
Dev Biol Stand; 1986; 58 ( Pt A)():365-9. PubMed ID: 3596042
[No Abstract] [Full Text] [Related]
51. New treatments for malignant melanoma.
Luce JK
Cancer Treat Rep; 1978 Dec; 62(12):2009. PubMed ID: 751710
[No Abstract] [Full Text] [Related]
52. Value of adjuvant therapy with bacille Calmette Guerin (BCG) or dimethl triazeno imidazole carboximide (DTIC) in the control of minimal residual disease in stage II melanoma.
Peter HH; Deutschmann KE; Deinhardt J; Deicher H
Recent Results Cancer Res; 1978; 68():367-74. PubMed ID: 752872
[No Abstract] [Full Text] [Related]
53. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
[TBL] [Abstract][Full Text] [Related]
54. Immunotherapy and immune competence of patients with malignant melanoma.
Kovarík J; Ninger E; Mechl Z; Zemanová D; Lauerová L; Sopková B; Svejda J; Bacovský B; Bártová A; Bártek J
Czech Med; 1983; 6(3):172-4. PubMed ID: 6416794
[No Abstract] [Full Text] [Related]
55. Induction of melanoma specific monocyte cytotoxicity in patients receiving BCG immunotherapy.
Dufour FD; Morton DL
Surg Forum; 1977; 28():165-7. PubMed ID: 617405
[No Abstract] [Full Text] [Related]
56. Combination of fibroblast interferon (HuIFN beta), carboxamide (DTIC), and cimetidine for advanced malignant melanoma.
Abdi EA; McPherson TA; Tan YH
J Biol Response Mod; 1986 Oct; 5(5):423-8. PubMed ID: 3772395
[TBL] [Abstract][Full Text] [Related]
57. [Unspecific immunological investigations in patients with malignant melanoma (author's transl)].
Knopf B; Wätzig V
Dermatol Monatsschr; 1982 Jan; 168(1):24-33. PubMed ID: 7044849
[No Abstract] [Full Text] [Related]
58. In vitro assay of cell-mediated immunity in BCG therapy of malignant melanoma: a preliminary report.
Nathanson L; Clark DA
Natl Cancer Inst Monogr; 1973 Dec; 39():221-4. PubMed ID: 4595321
[No Abstract] [Full Text] [Related]
59. [Basis for a specific-active immunotherapy in malignant melanoma].
Mutzner PA; Stuhlmiller GM; Seigler HF; Stumpf WE; Sar M
Schweiz Med Wochenschr; 1981 Sep; 111(36):1322-5. PubMed ID: 7302537
[TBL] [Abstract][Full Text] [Related]
60. Immunotherapy of melanoma with intralesional BCG.
Bornstein RS; Mastrangelo MJ; Sulit H; Chee D; Yarbro JW; Prehn LM; Prehn RT
Natl Cancer Inst Monogr; 1973 Dec; 39():213-20. PubMed ID: 4595320
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
